About 3DHEALS Company Directory:
3DHEALS updates this collection of public and private companies, government and non-government institutions, and any relevant research organizations in healthcare 3D printing, bioprinting, AR/VR, 3D technologies, on a weekly basis. Access to this directory is free to 3DHEALS Premium and Enterprise members.
THIS CONTENT IS FOR PREMIUM AND ENTERPRISE MEMBERS ONLY.

Precise Bio
Precise Bio is a regenerative medicine company that is advancing the use of bio-printed tissues and organs in patients in ophthalmology and is building a broad portfolio of R&D programs in additional medical disciplines.
Headquarters 111 North Chestnut St. Winston-Salem NC 27101 USADetails
Precise Bio is a regenerative medicine company advancing the use of bio-printed tissues and organs in patients in ophthalmology and building a broad portfolio of R&D programs in additional medical disciplines.
The company’s commercial and R&D programs are based on its innovative 4D-bio-fabrication technology. This innovative platform comprises cell expansion, bio-materials, processes, printing technology, and other critical technologies leading the way toward generating a robust pipeline of proprietary products with substantial clinical and commercial value.
The company’s robust technology platform allows it to advance its fabricated human cornea program concurrent with developing other organs and tissues for use in ophthalmic indications. Moreover, the company’s technology overcomes multiple challenges in scalable, reproducible manufacturing of bio-printed tissues and organs.
The company maintains offices, laboratories and production facilities in North Carolina, in the U.S. and in Shoham, Israel.
Today there is only one available cornea for every 70 needed by patients throughout the world. The Precise Cornea uses cells to form a fully functional bio-fabricated, corneal implant, designed to achieve superior quality, cell density, transparency, and mechanical properties.
Precise Bio has executed the first animal Descemet’s Stripping Endothelial Keratoplasty (DSEK) corneal transplant. In addition, the company’s pipeline includes a Descemet’s Membrane Endothelial keratoplasty (DMEK) implant and the same technology will be applied for Penetrating Keratoplasty (PK) implant. These will offer a complete solution for corneal transplantation needs and alleviate the shortage in donated corneas.
Based on the company’s website, it seems that several future products include the following:
- Retinal patch: Targeted treatment for Age-related macular degeneration (AMD)
- Vision correction lenticules (implant): Offering a new approach to solving refractive errors
- Ocular surface disorders: Targeting various conditions involving damagedcornea surface or Limbal Stem Cell Deficiency